Exploring the First FDA-Approved Treatment to Delay T1D Onset: Mechanism of Action and Treatment Impact

The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.

The patient, an active 49-year-old man, had an HbA1c of 8.6 after diabetes was first diagnosed. It’s now 7.6 with metformin and lifestyle measures. Is the current A1c goal adequate, or should you treat more aggressively?

Find details on challenges primary care clinicians face in treating older adults with T2D and an expert discussion on navigating treatments to delay T1D.

Hypoglycemia in type 2 diabetes patients can be the result of insulin or sulfonylureas.

The only CGM system cleared for 1 year of use in type 1 and 2 diabetes is expected to be available in the fourth quarter of this year, the manufacturers said.

EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.